Results: For all tested needle shapes, the maximum absolute difference between the fiber optic based and the goldstandard values was lower than 0.9mm (Experiment #1, Fig.  1b and 1c ). Over the 4 tested catheters, the maximal absolute difference between MR-and fiber optic based measurements was lower than 0.9mm (Experiment #2, Fig.  1e, 1f and 1g ).
Conclusion:
This study demonstrates that the employed fiber optic tracking device is able to monitor the needle bending during MR-imaging with an accuracy and update rate eligible for MR-guided intervention. Purpose or Objective: MOSkin detectors coupled to a transrectal ultrasound (TRUS) probe were used to perform in vivo dosimetry (IVD) on the rectal wall surface during US-based HDR prostate brachytherapy (BT). The system, called dual purpose probe (DPP), has proven to be an accurate tool to measure in vivo the integral dose, however discrepancies between planned and measured doses from each single catheter can be much higher than the overall discrepancies. In this work, three HDR prostate BT sessions were studied to find a possible distance and angle dependence correction function (CF) to be applied in real time to each single catheter, and data with and without the application of the obtained CF were compared.
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Material and Methods:
The DPP can be sketched as follows: four MOSkin dosimeters are firmly attached to TRUS rectal probe and are connected to a multichannel reader which provides measurements of the voltage shifts (proportional to the dose) in the MOSkin sensitive layer caused by radiation exposure. A dedicated software plots and records the measured dose with each MOSkin as a function of time, allowing the identification of the dose contribution of each single catheter in real time. Based on the treatment plan data (i.e. planned source strength, dwell times and positions) a software was implemented in the Matlab environment to compute the dose contribution to the MOSkin from each catheter based on TG-43 algorithm. The software reports also the weighted average distance of source to MOSkin for each catheter and the resulting weighted polar angles. IVD data were acquired on three patients treated between June and October 2015 and retrospectively analysed, providing 141 dose measurements for all the MOSkins. Measured and calculated contributions by each single catheter were quantified separately. Discrepancies were plotted depending on weighted average polar angles and distances between MOSkins and source, and a linearly fitting CF was calculated.
Results:
A correction function CF linearly depending on the weighted average distance and polar angle of the catheter from the dosimeter was obtained (R=0.35, showing a significant correlation). The results showed an increase in sensitivity of MOSkins at higher distances (i.e., due to radiation softening) and at wider polar angles (i.e., due to increased radiation contamination by the presence of the TRUS probe). The percentage dose discrepancy between calculated and measured dose contribution from each single catheter with and without the application of obtained CF resulted in 1.3±13.1% and 1.2±7.7% (k=1), respectively (figure 1).
Conclusion:
The use of the CF significantly reduces percentage discrepancy between planned and measured dose per single catheter. Implementation of the CF to correct MOSkin readings online is a further step towards accurate and reliable real time IVD in prostate BT performed with the DPP. Based on the real time measured dose discrepancy, the next step will be defining an action protocol to use the acquired information online. is an intensity modulated high dose rate (HDR) BT treatment technique, where radiation sources are surrounded by catheters containing rotating shields that direct radiation towards the tumour and away from healthy tissues. RSBT for HDR requires sources with lower energies than Ir-192, such as Gd-153 and Se-75, due to shield thickness constraints. The distinct features of shield angle, catheter material and source isotope require the development of a specific Monte Carlo (MC)-based treatment planning and optimization system.
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Material and Methods:
An MC based dose calculation engine for RSBT has been developed and coupled with a columngeneration optimizer. At every iteration of the optimization loop, the column-generation process solves a pricing problem to determine the best dwell position and shield angle combination to add to the treatment plan, resulting in the best possible plan with the shortest treatment time. As a source model, the microSelectron-v2 source geometry was selected and placed inside a cylindrical platinum shield with a diameter of 1.8 mm and 3.0 mm for interstitial and intracavitary cases, respectively. An emission window coinciding with the active core of the source was created by removing half (180º) of the wall of the shield. For an interstitial prostate case, RSBT plans were generated only using Gd-153 as a source due to the extreme limitations on shield size in interstitial catheters. For the intracavitary GYN case, both Gd-153 and Se-75 plans were generated. All RSBT plans were compared with conventional HDR BT. Only the original dwell positions used in conventional BT were sampled to create the RSBT plans.
Results: RSBT plans resulted in a considerable reduction in both rectum and bladder doses without sacrificing target coverage for the prostate case. With 95% of the PTV volume receiving over 15 Gy, only 40% of the rectum volume received more than 2 Gy for the Gd-153 RSBT case,as opposed to 85% for the unshielded Ir-192 conventional plan.
